Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

BACKGROUND: Safe and effective treatments are urgently needed for patients with relapsed/refractory acute myeloid leukaemia (AML). We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone derivative, plus cytarabine in patients with relapsed/refractory AML. METHODS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet Oncol
Hauptverfasser: Ravandi, Farhad, Ritchie, Ellen K., Sayar, Hamid, Lancet, Jeffrey E., Craig, Michael D., Vey, Norbert, Strickland, Stephen A., Schiller, Gary J., Jabbour, Elias, Erba, Harry P., Pigneux, Arnaud, Horst, Heinz-August, Recher, Christian, Klimek, Virginia M., Cortes, Jorge, Roboz, Gail J., Odenike, Olatoyosi, Thomas, Xavier, Havelange, Violaine, Maertens, Johan, Derigs, Hans-Günter, Heuser, Michael, Damon, Lloyd, Powell, Bayard L., Gaidano, Gianluca, Carella, Angelo-Michele, Wei, Andrew, Hogge, Donna, Craig, Adam R., Fox, Judith A., Ward, Renee, Smith, Jennifer A., Acton, Gary, Mehta, Cyrus, Stuart, Robert K., Kantarjian, Hagop M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822512/
https://ncbi.nlm.nih.gov/pubmed/26234174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00201-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge